CCR2 inhibition reduces tumor myeloid cells and unmasks a checkpoint inhibitor effect to slow progression of resistant murine gliomas
Joseph Flores‐Toro(National Cancer Institute), Jeffrey K. Harrison(Scripps Research Institute), Meenal Datta(University of Notre Dame), Defang Luo(University of Florida), Matthew R. Sarkisian(University of Florida), Thomas J. Schall(ChemoCentryx (United States)), Duane A. Mitchell(University of Florida), Rajinder Singh(ChemoCentryx (United States)), James J. Campbell(Harvard University), Adithya Gopinath(University of Florida), Israel Charo(Gladstone Institutes), Rakesh K. Jain(Massachusetts General Hospital)
Cited by 330
Related Papers
Identification of a major co-receptor for primary isolates of HIV-1
|Nature|1996|3.7k
A new class of membrane-bound chemokine with a CX3C motif
|Nature|1997|2k
Identification and Molecular Characterization of Fractalkine Receptor CX3CR1, which Mediates Both Leukocyte Migration and Adhesion
|Cell|1997|1.5k
Selective attraction of monocytes and T lymphocytes of the memory phenotype by cytokine RANTES
|Nature|1990|1.4k
A novel chemokine receptor for SDF-1 and I-TAC involved in cell survival, cell adhesion, and tumor development
|The Journal of Experimental Medicine|2006|1.3k